March 9 () - GSK said on Monday it will receive up ‌to $690 million from Italian pharmaceutical ‌company Alfasigma for the ...

Naturally occurring chemicals in cannabis have been shown to reduce cholesterol–and the risk of deadly fatty liver disease, ...

As 1 out of every 3 adults worldwide suffers from the condition, Hebrew University scientists use non-psychoactive substances ...

Mayo Clinic researchers have identified a rare mutation in the MET gene that can directly cause metabolic dysfunction-associated steatotic liver disease. The mutation disrupts the liver’s ability to ...

A new scientific study reveals that two key cannabis compounds work by creating a backup energy reserve in the liver. The post Study reveals cannabis compounds reduce threat of fatty liver disease ...

In experiments on pigs, researchers found that some formula fats can strain the newborn liver far earlier than expected.

CBD and CBG, two non-intoxicating cannabis compounds, may help combat fatty liver disease by boosting liver energy reserves ...

Sorbitol, a common sugar alcohol used in zero-calorie foods and found naturally in some fruits, isn’t just a passive ...

Researchers have discovered that non-psychoactive cannabis compounds, CBD and CBG, can significantly reduce liver fat and ...

On World Obesity Day 2026, know why fatty liver disease is rising in India, its risks, and expert-backed prevention ...

GSK has ​agreed to ‌sell its worldwide ​rights ​to develop and ⁠commercialise its ​experimental ​liver disease drug ...